The New York Times Agency May 2010
EN_00913897_8578
(NYT41) HOUSTON -- March 12, 2003 -- PEANUT-ALLERGY-DRUG -- Tiny Tanox Inc. should be on the verge of triumph. A drug it developed made headlines this week when it was shown to blunt peanut allergies, protecting people who could die after eating even a fraction of a peanut. But the future of the drug is now in doubt because of a series of legal disputes dating back more than ten years. And the husband-and-wife scientists who started Tanox, a Houston-based biotechnology company, may find that even if the drug does reach the market, most of the revenue will go to other companies. A scientist prepares growth medium at a Tanox Inc. laboratory in Houston, March 12, 2003. (Michael Stravato/The New York Times)
CENA MINIMALNA - 100 USD
2003-03-12
EAST NEWS
The New York Times Agency
Michael Stravato/The New York Times/Redux
16417421
0,71MB
25cm x 19cm przy 300dpi
12, 2003, A, AFTER, ALLERGIES, AND, AT, BACK, BE, BECAUSE, BIOTECHNOLOGY, BLUNT, BUT, COMPANIES, COMPANY, COULD, DATING, DEVELOPED, DIE, DISPUTES, DOES, DOUBT, DRUG, EATING, EVEN, FIND, FRACTION, FUTURE, GO, GROWTH, HEADLINES, HOUSTON, HOUSTON-BASED, IF, IN, INC, IS, IT, LABORATORY, LEGAL, MADE, MARCH, MARKET, MAY, MEDIUM, MICHAEL, MORE, MOST, NEW, NOW, NYT41, OF, ON, OTHER, PEANUT, PEOPLE, PREPARES, PROTECTING, REACH, REDUX, REVENUE, SCIENTIST, SCIENTISTS, SERIES, SHOULD, SHOWN, STARTED, STRAVATO, TANOX, TEN, THAN, THAT, THE, THIS, TIMES, TINY, TO, TRIUMPH, VERGE, WAS, WEEK, WHEN, WHO, WILL, YEARS, YORK,